MannKind's inhaled diabetes treatment wins FDA panel support

04/2/2014 | Reuters

An FDA advisory panel endorsed the approval of MannKind's inhaled insulin therapy Afrezza as a treatment for type 1 and type 2 diabetes. Afrezza could especially benefit type 2 diabetes patients who have difficulty injecting themselves with insulin because of poor eyesight or hand arthritis, as well as patients with extreme fear of needles, the panel said. A final decision is expected by April 15.

View Full Article in:

Reuters

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Paralegal, Legal-Regulatory
Confidential
Piscataway, NJ